We have updated our publications page with recent papers from our BronchUK collaborators. Abstracts and links to full texts are available - why not take a look: https://www.bronch.ac.uk/latest-publications 

You will find further information on the following:

1. Characterisation of Eosinophilic Bronchiectasis: A European Multicohort Study.

Shoemark A, Shteinberg M, De Soyza A, Haworth C, Richardson H, Gao Y, Perea L, Dicker AJ, Goeminne PC, Cant E, Polverino E, Altenburg J, Keir HR, Loebinger MR, Blasi F, Welte T, Sibila O, Aliberti S, Chalmers JD.

Am J Respir Crit Care Med. 2022 Jan 20. doi: 10.1164/rccm.202108-1889OC. Online ahead of print.

PMID: 35050830

2. Heterogeneity of treatment response in bronchiectasis clinical trials.

Sibila O, Laserna E, Shoemark A, Perea L, Bilton D, Crichton ML, De Soyza A, Boersma WG, Altenburg J, Chalmers JD.

Eur Respir J. 2021 Oct 21:2100777. doi: 10.1183/13993003.00777-2021. Online ahead of print.

PMID: 34675045

3. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.

Aliberti S, Goeminne PC, O'Donnell AE, Aksamit TR, Al-Jahdali H, Barker AF, Blasi F, Boersma WG, Crichton ML, De Soyza A, Dimakou KE, Elborn SJ, Feldman C, Tiddens H, Haworth CS, Hill AT, Loebinger MR, Martinez-Garcia MA, Meerburg JJ, Menendez R, Morgan LC, Murris MS, Polverino E, Ringshausen FC, Shteinberg M, Sverzellati N, Tino G, Torres A, Vandendriessche T, Vendrell M, Welte T, Wilson R, Wong CA, Chalmers JD.

Lancet Respir Med. 2021 Sep 24:S2213-2600(21)00277-0. doi: 10.1016/S2213-2600(21)00277-0. Online ahead of print.

PMID: 34570994 Review.

4. Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis.

Gao YH, Abo Leyah H, Finch S, Lonergan M, Aliberti S, De Soyza A, Fardon TC, Tino G, Chalmers JD.

Am J Respir Crit Care Med. 2020 Jun 15;201(12):1499-1507. doi: 10.1164/rccm.201910-1972OC.

PMID: 32097051 Clinical Trial.

5. A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial.

Bradley JM, Anand R, O'Neill B, Ferguson K, Clarke M, Carroll M, Chalmers J, De Soyza A, Duckers J, Hill AT, Loebinger MR, Copeland F, Gardner E, Campbell C, Agus A, McGuire A, Boyle R, McKinney F, Dickson N, McAuley DF, Elborn S; CLEAR study group.

Trials. 2019 Dec 19;20(1):747. doi: 10.1186/s13063-019-3766-9.

PMID: 31856887 Free PMC article.

6. British Thoracic Society Guideline for bronchiectasis in adults.

Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, Hiscocks E, Hurst JR, Johnson C, Kelleher PW, Bedi P, Payne K, Saleh H, Screaton NJ, Smith M, Tunney M, Whitters D, Wilson R, Loebinger MR.

Thorax. 2019 Jan;74(Suppl 1):1-69. doi: 10.1136/thoraxjnl-2018-212463.

PMID: 30545985 No abstract available.

7. Quality control for multiple breath washout tests in multicentre bronchiectasis studies: Experiences from the BRONCH-UK clinimetrics study.

O'Neill K, Lakshmipathy GR, Ferguson K, Cosgrove D, Hill AT, Loebinger MR, Carroll M, Chalmers JD, Gatheral T, Johnson C, DeSoyza A, Hurst JR, Bradbury I, Elborn JS, Bradley JM.

Respir Med. 2018 Dec;145:206-211. doi: 10.1016/j.rmed.2018.10.030. Epub 2018 Nov 1.

PMID: 30509710